XML 62 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
Business Combination - Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
12 Months Ended
Jun. 01, 2016
Dec. 31, 2017
Dec. 31, 2016
Amounts Recognized      
Goodwill   $ 155,593 $ 155,593
Licensed IP      
Amounts Recognized      
Weighted average useful life   12 years 6 months  
ARIAD Pharmaceuticals      
Amounts Recognized      
Current assets $ 21,363    
Property and equipment 850    
Restricted cash 432    
Intangible assets 283,000    
Total identifiable assets 305,645    
Current liabilities (15,538)    
Other long term liabilities (5,226)    
Total liabilities assumed (20,764)    
Goodwill 155,593    
Total fair value of consideration transferred $ 440,474    
ARIAD Pharmaceuticals | Maximum      
Amounts Recognized      
Development costs   $ 7,000 $ 7,000
ARIAD Pharmaceuticals | Licensed IP      
Amounts Recognized      
Discount rate (as a percent) 15.00%    
Gross margins (as a percent) 98.00%    
Weighted average useful life 12 years 6 months    
ARIAD Pharmaceuticals | Licensed IP | Minimum      
Amounts Recognized      
Tax rates (as a percent) 7.80%    
ARIAD Pharmaceuticals | Licensed IP | Maximum      
Amounts Recognized      
Tax rates (as a percent) 13.80%    
ARIAD Pharmaceuticals | IPR&D      
Amounts Recognized      
Probability of technical success (“PTS”) (as a percent) 25.00%    
Discount rate (as a percent) 16.00%    
Gross margins (as a percent) 98.00%    
ARIAD Pharmaceuticals | IPR&D | Minimum      
Amounts Recognized      
Tax rates (as a percent) 7.80%    
ARIAD Pharmaceuticals | IPR&D | Maximum      
Amounts Recognized      
Tax rates (as a percent) 13.80%